CJC-1295 (No DAC) vs PNC-27: Mechanism, Half-Life & Research Use

Executive Direct Comparison: CJC-1295 (No DAC) vs PNC-27

In laboratory evaluation, cjc-1295 (no dac) vs pnc-27 represent two completely distinct therapeutic classes of research compounds. CJC-1295 (No DAC), also recognized as Modified GRF (1-29), is a 29-amino-acid tetrasubstituted peptide analog of endogenous GHRH designed to stimulate the anterior pituitary gland to release growth hormone (GH) in a physiologic, pulsatile manner.

Conversely, PNC-27 is a specialized chimeric peptide combining a p53-derived HDM-2-binding domain with a transmembrane-penetrating leader sequence. Its primary utility in laboratory research lies in oncology and membrane-lysis assays, where it interacts with surface-expressed HDM-2 proteins on transformed cell lines to trigger rapid, non-apoptotic transmembrane pore formation and cell lysis. Researchers selecting between these compounds are generally investigating entirely divergent pathways: neuroendocrine signaling and somatotropic activation versus cell membrane disruption and targeted cytotoxicity.

Comparative Specifications & Property Matrix

To assist laboratory personnel in protocol selection and experimental design, the table below outlines the primary physicochemical and functional properties of CJC-1295 (No DAC) alongside PNC-27:

• Primary Receptor Target: GHRH Receptor (GHRHR) in anterior pituitary (CJC-1295 No DAC) vs. Membrane-bound HDM-2 / MDM2 protein complexes (PNC-27). • Mechanistic Class: Growth Hormone-Releasing Hormone (GHRH) Secretagogue / Analog (CJC-1295 No DAC) vs. Membrane-Active Cytolytic / Cell-Penetrating Peptide (PNC-27). • Reported Plasma Half-Life: Approximately 30 minutes in vivo (CJC-1295 No DAC) vs. Short enzymatic degradation profile, active primarily in immediate in vitro contact assays (PNC-27). • Primary Solubility: Highly soluble in sterile aqueous buffers and standard diluents (CJC-1295 No DAC) vs. Soluble in aqueous buffer; requires careful pH management to prevent aggregation (PNC-27). • Typical Preclinical Models: Rodent metabolic, somatotropic axis, and tissue repair assays (CJC-1295 No DAC) vs. In vitro transformed cell lines and solid tumor xenograft models (PNC-27). • Available Formulations: 2mg and 5mg lyophilized vials via PX1 Research (CJC-1295 No DAC) vs. Specialty research-grade lyophilized vials (PNC-27).

CJC-1295 (No DAC) Biochemical Profile and GHRH Receptor Kinetics

CJC-1295 (No DAC) is a synthetic modification of the natural growth-hormone-releasing hormone fragment GRF (1-29). Native GHRH undergoes rapid cleavage by dipeptidyl peptidase-IV (DPP-IV) at the Alanine-2 position, resulting in an extremely short in vivo half-life of less than 7 minutes. CJC-1295 (No DAC) incorporates four strategic amino acid substitutions—specifically Tyr-1, Ala-2, Asp-3, and Ala-15—which shield the N-terminal chain from enzymatic degradation while preserving high binding affinity for the GHRH receptor on pituitary somatotropes.

In preclinical research models, CJC-1295 (No DAC) acts as a selective GHRH receptor agonist. Binding triggers a G-protein-coupled signal transduction cascade that elevates intracellular cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) levels. This cascade promotes the synthesis and pulsatile release of endogenous growth hormone without ablating natural feedback loops. Consequently, downstream serum levels of Insulin-like Growth Factor 1 (IGF-1) are augmented, making CJC-1295 (No DAC) a core compound for investigating collagen synthesis, nitrogen retention, musculoskeletal matrix repair, and systemic metabolic homeostasis. Researchers frequently source this peptide across our catalog of high-purity all peptides for longitudinal somatotropic axis assays.

PNC-27 Mechanism of Action: Membrane Target Interaction and Cytolysis

PNC-27 is a synthetic, 32-amino-acid chimeric peptide constructed by coupling residues 12–26 of the human p53 tumor suppressor protein to a hydrophobic, cell-penetrating leader sequence (MRP or penetratin derived). Unlike traditional p53-based research compounds designed to activate intracellular apoptotic pathways via nuclear transport, PNC-27 operates primarily at the plasma membrane level.

Preclinical studies demonstrate that many malignant and transformed cell lines abnormally express HDM-2 (Human Double Minute 2) protein complexes directly within their plasma membranes. PNC-27 specifically binds to the HDM-2 protein on these target membranes. Upon binding, the amphipathic alpha-helical domain of PNC-27 inserts into the lipid bilayer, creating non-selective transmembrane pores. This rapid membrane destabilization causes extracellular fluid influx, swelling, and osmotic lysis of target cells within hours, independent of classic caspase-dependent apoptotic pathways. In vitro assays evaluating PNC-27 focus heavily on membrane permeability dynamics, cancer cell selectivity, and resistance to standard apoptotic inhibition.

Structural Dynamics and Half-Life Divergence

The pharmacokinetics and structural stability of CJC-1295 (No DAC) and PNC-27 highlight fundamental operational differences between endocrine secretagogues and cytolytic peptides. CJC-1295 (No DAC) exhibits a half-life of roughly 30 minutes in animal models. Because it lacks the Drug Affinity Complex (DAC) maleimide-propionic acid linker that binds to circulating serum albumin, CJC-1295 (No DAC) clears rapidly enough to permit normal physiological pulsing of growth hormone rather than continuous receptor activation.

PNC-27, on the other hand, does not rely on extended endocrine circulation to execute its function. Its half-life in physiological media is brief due to susceptibility to ubiquitous serum proteases; however, its primary cytolytic mechanism occurs rapidly upon direct exposure to target membranes. In cellular culture assays, membrane disruption is typically observable within 30 to 180 minutes of incubation. Consequently, experimental protocols involving PNC-27 prioritize direct localized administration or serum-free culture environments, whereas CJC-1295 (No DAC) protocols evaluate systemic endocrine responses over hours to days.

Preclinical Study Designs: Metabolic and Tissue Repair Models

Researchers select CJC-1295 (No DAC) when designing studies centered on GHRH pathway activation and downstream metabolic regulation. Preclinical rodent models investigating muscle wasting, tendon healing, bone mineral density, and adipose tissue lipolysis frequently utilize CJC-1295 (No DAC) to induce physiologically relevant GH peaks.

Because it preserves natural feedback mechanisms, researchers can evaluate the synergistic effects of combining CJC-1295 (No DAC) with ghrelin mimetics or GHRPs (such as Ipamorelin) to analyze maximal pituitary GH secretion capacity. Furthermore, CJC-1295 (No DAC) is widely used in anti-aging and cellular senescence research models to quantify how restored IGF-1 signaling affects cellular repair mechanisms, mitochondrial function, and nitrogen balance.

Preclinical Study Designs: Targeted Cytotoxicity and Oncology Assays

Conversely, study designs incorporating PNC-27 are centered on oncology, membrane biology, and targeted drug delivery systems. Because PNC-27 selectively targets cells with high membrane-bound HDM-2 expression—a phenotype common in transformed tumor cells but generally absent in untransformed non-malignant somatic cells—it serves as a model compound for targeted membrane lysis.

Laboratory assays utilizing PNC-27 measure parameters such as lactate dehydrogenase (LDH) release, propidium iodide uptake, electron microscopic visualization of membrane pore formation, and cell viability in heterogeneous co-culture models. PNC-27 is frequently studied alongside control peptides (such as PNC-28, a related construct with a different binding region) to evaluate the structural requirements for selective membrane destruction in preclinical cancer research.

Topical Peptide Spectrum: Class Comparisons in Endocrine and Membrane Dynamics

To properly contextualize these compounds within a broader chemical landscape, researchers must examine related analogs in the endocrine and cell-penetrating categories. When investigating the somatotropic axis, CJC-1295 (No DAC) is often evaluated against cjc-1295-dac, which incorporates a covalent albumin-binding moiety that extends the half-life to over 6 days for continuous receptor stimulation. Additionally, investigators frequently compare CJC-1295 (No DAC) with short-acting GHRH analogs such as sermorelin or combine it with selective ghrelin receptor agonists like ipamorelin to map multi-receptor secretagogue dynamics. In contrast, membrane-active agents like PNC-27 occupy an entirely separate functional spectrum alongside pore-forming antimicrobials and cell-penetrating vectors, demonstrating how structural modifications dictate completely distinct biochemical targets across our research catalog.

Reconstitution, Stability, and Laboratory Handling Protocols

Both CJC-1295 (No DAC) and PNC-27 are supplied as highly purified, lyophilized powders to ensure maximum chemical stability during transport and storage. Upon arrival, vials should be stored immediately in a temperature-controlled freezer at -20°C. Prior to reconstitution, vials must be allowed to acclimate to ambient room temperature to prevent condensation within the matrix.

Reconstitution should be performed using sterile bacteriostatic water or laboratory-grade phosphate-buffered saline (PBS), depending on the requirements of the downstream assay. For accurate concentration calculations and diluent volumetric mapping, researchers should consult our interactive reconstitution calculator. Gently swirl the vial to dissolve the cake; aggressive agitation or shaking should be strictly avoided to prevent mechanical shear stress and peptide aggregation. Reconstituted solutions should be aliquoted and stored at 4°C for immediate short-term use, or frozen at -80°C to maintain structural integrity across extended research timelines.

Analytical Quality Standards: HPLC, MS, and Endotoxin Verification

Reliable preclinical research depends entirely on the analytical purity and lot-to-lot consistency of the subject reagents. PX1 Research adheres to stringent quality control frameworks, ensuring all compounds are manufactured in GMP-compliant facilities within the USA and verified by independent ISO 17025 accredited laboratories.

Every production lot undergoes rigorous High-Performance Liquid Chromatography (HPLC) to confirm peptide purity exceeds 99%, alongside Mass Spectrometry (MS) to verify exact molecular weight and amino acid sequence fidelity. Furthermore, bacterial endotoxin testing (LAL assay) is conducted to guarantee that endotoxin levels remain well below published threshold limits for cell culture and preclinical administration. Researchers can access lot-specific analytical documentation at any time via our public COA repository. To inquire about volume purchasing or specialized research supply agreements, visit our wholesale portal.